Press release
Primary Sclerosing Cholangitis Pipeline Progresses as 14+ Pharma Companies Advance Novel Liver Disease Therapies, Finds DelveInsight | Gilead Sciences, Immunic, LISCure Biosciences, Mirum Pharmaceuticals, Ipsen
Primary Sclerosing Cholangitis treatment Pipeline
Explore the latest breakthroughs in the Primary Sclerosing Cholangitis treatment landscape. Learn more about the evolving PSC pipeline today @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Primary Sclerosing Cholangitis Pipeline Report
• In September 2025, Mirum Pharmaceuticals completed enrollment in the Phase IIb VISTAS trial evaluating volixibat, an oral IBAT inhibitor, for cholestatic pruritus in PSC.
• In April 2025, late-breaking data demonstrated that elafibranor demonstrated dose-dependent efficacy and a favorable safety profile over 12 weeks in patients with PSC.
• In 2024, the volixibat study met its prespecified efficacy and safety criteria at a blinded interim analysis for dose selection, highlighting its encouraging clinical potential.
• Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation, fibrosis, and destruction of intra- and extrahepatic bile ducts.
• DelveInsight's Primary Sclerosing Cholangitis Pipeline Insight report depicts a growing clinical development space with 14+ active players advancing over 14 pipeline therapies for PSC treatment.
• Gilead Sciences is advancing one of the leading candidates, GS-9674 (Cilofexor), a nonsteroidal FXR agonist that has reached Phase III clinical trials.
• Ipsen's Elafibranor, an oral agonist of PPAR α and δ, recently demonstrated positive results in a Phase II trial, reducing bile acid toxicity and improving cholestasis.
• Leading Primary Sclerosing Cholangitis companies include LISCure Biosciences, Mirum Pharmaceuticals, Ipsen, Chemomab Therapeutics, Gilead Sciences, and Immunic.
• Promising Primary Sclerosing Cholangitis therapies in development include LB-P8, Volixibat, IQIRVO (Elafibranor), Nebokitug, Cilofexor, and IMU-838.
Download for updates and the latest revolution in PSC care @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Primary Sclerosing Cholangitis Emerging Drugs Profile
• Cilofexor (GS-9674): Gilead Sciences
Cilofexor is a nonsteroidal farnesoid X receptor (FXR) agonist being developed by Gilead Sciences. FXR is highly expressed in the liver and intestine and plays a key role in bile acid homeostasis. By activating FXR, Cilofexor aims to regulate bile acid synthesis and transport, thereby reducing cholestasis and liver injury. It is currently one of the most advanced candidates in the pipeline, having reached Phase III clinical evaluation for the treatment of Primary Sclerosing Cholangitis.
• IMU-838: Immunic
IMU-838 (vidofludimus calcium) is an investigational oral small molecule drug that acts as a next-generation selective dihydroorotate dehydrogenase (DHODH) inhibitor. The drug is designed to inhibit the metabolism of activated T and B cells while leaving other immune cells largely unaffected. This targeted approach aims to reduce the chronic inflammation associated with PSC. Currently, IMU-838 is in Phase II clinical trial evaluation for the treatment of Primary Sclerosing Cholangitis.
• Volixibat: Mirum Pharmaceuticals
Volixibat is an investigational, oral, minimally absorbed inhibitor of the ileal sodium-dependent bile acid transporter (IBAT). By blocking IBAT, volixibat is designed to increase the excretion of bile acids, thereby reducing the bile acid pool and potentially alleviating symptoms like cholestatic pruritus. Mirum Pharmaceuticals is evaluating volixibat in the Phase IIb VISTAS trial. The study met its pre-specified efficacy and safety thresholds at a 2024 interim analysis, with topline results expected in Q2 2026.
For more information on the Primary Sclerosing Cholangitis Emerging Drugs Profile, download DelveInsight's comprehensive Primary Sclerosing Cholangitis Pipeline Insight report @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The Primary Sclerosing Cholangitis Pipeline Report Provides
• Detailed insights about companies developing therapies for Primary Sclerosing Cholangitis, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for PSC treatment.
• PSC companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• PSC drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, and molecular type.
• Detailed analysis of collaborations, licensing agreements, and financing details for future advancement of the Primary Sclerosing Cholangitis market.
Learn more about Primary Sclerosing Cholangitis drug opportunities in our comprehensive PSC pipeline report @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Primary Sclerosing Cholangitis Companies and Competitive Landscape
There are 14+ key companies, including Gilead Sciences, Immunic, LISCure Biosciences, Mirum Pharmaceuticals, Ipsen, Chemomab Therapeutics, and others, developing therapies for Primary Sclerosing Cholangitis, with Gilead Sciences having its PSC drug candidate in the most advanced Phase III stage.
DelveInsight's Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type
Primary Sclerosing Cholangitis products have been categorized under various Molecule types such as:
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Discover the latest advancements in Primary Sclerosing Cholangitis treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Scope of the Primary Sclerosing Cholangitis Pipeline Report
• Coverage: Global
• Primary Sclerosing Cholangitis Companies: Gilead Sciences, Immunic, LISCure Biosciences, Mirum Pharmaceuticals, Ipsen, Chemomab Therapeutics, and others.
• Primary Sclerosing Cholangitis Therapies: Cilofexor (GS-9674), IMU-838, Volixibat, LB-P8, Nebokitug, IQIRVO (Elafibranor), and others.
• Primary Sclerosing Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Primary Sclerosing Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Pipeline Progresses as 14+ Pharma Companies Advance Novel Liver Disease Therapies, Finds DelveInsight | Gilead Sciences, Immunic, LISCure Biosciences, Mirum Pharmaceuticals, Ipsen here
News-ID: 4500160 • Views: …
More Releases from DelveInisight Business Research
Achondroplasia Pipeline Expands as 15+ Pharma Companies Advance Targeted Therapi …
DelveInsight's "Achondroplasia - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies developing several pipeline drugs in the achondroplasia pipeline landscape. It covers the achondroplasia pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the achondroplasia treatment landscape. Learn more about the…
Cutaneous T-Cell Lymphoma (CTCL) Clinical Trial Pipeline Analysis: 25+ Key Compa …
DelveInsight's Cutaneous T-Cell Lymphoma (CTCL) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline CTCL therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CTCL pipeline domain.
Key takeaways from the CTCL Clinical Trial Landscape Report
• DelveInsight's CTCL pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies…
Chronic Spontaneous Urticaria Market Size in the 7MM is Projected to Enhance at …
The market dynamics for Chronic Spontaneous Urticaria (CSU) is witnessing significant growth driven by the rising prevalence of chronic inflammatory skin disorders, increasing diagnosis rates, improved disease awareness, and higher treatment-seeking behavior among patients with persistent hives and angioedema. Growing demand for targeted biologics, better access to specialty care, and expanding use of advanced immunomodulatory therapies are further supporting market expansion. Additionally, the launch of emerging therapies such as barzolvolimab…
Chronic Kidney Disease Market Size in the 7MM is Projected to Enhance at a Signi …
The market dynamics for Chronic Kidney Disease (CKD) is witnessing significant growth driven by the rising prevalence of diabetes, hypertension, obesity, and aging populations, which are major contributors to declining kidney function. Increasing awareness regarding early diagnosis, growing screening initiatives, and higher treatment uptake are further supporting market expansion. Additionally, the launch of emerging therapies such as atrasentan, zibotentan/dapagliflozin, and other novel renal-protective agents will further fuel the market.
DelveInsight's "Chronic…
More Releases for Primary
Premier Primary Care Medicine Recognized as a Top Primary Care Doctor in Smyrna, …
Premier Primary Care Medicine has been recognized as one of the Top Primary Care Doctors in Smyrna, GA, a distinction that underscores the practice's dedication to delivering high-quality, patient-focused healthcare to the local community. This recognition affirms the practice's strong reputation for clinical expertise, compassionate service, and commitment to improving long-term health outcomes for patients across Smyrna and surrounding areas.
SMYRNA, GA - March 3, 2026 - Premier Primary Care [https://www.premierpcmed.com/]…
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
